See also this year's filing and all EDGAR filings for this company.
PDF Report 0001426332_2023_NGM_Biopharmaceuticals_INC.pdf
Logs
| warning | The stock price does not exist | industry.us_generic | {} |
| warning | Similarly named company. Duplicate? | None | {'details': [{'other_company': 'Provectus Biopharmaceuticals INC', 'shared_tokens': {'biopharmaceuticals'}}, {'other_company': 'Regenerx Biopharmaceuticals INC', 'shared_tokens': {'biopharmaceuticals'}}]} |
Graph
Absolute values for 0001426332, NGM Biopharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 288,859,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 8,496,000 |
| 3 | remainder_Assets | 10,047,000 |
| 4 | LiabilitiesCurrent | 47,842,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 41,624,017 |
| 9 | ResearchAndDevelopmentExpense | 187,296,503 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 57,714,486 |
| 12 | remainder_NetIncome | 2,558,620 |
| 13 | remainder_ComprehensiveNetIncome | -164,614 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 307,402,000 |
| 1 | Liabilities | 47,842,000 |
| 2 | Expenses | 228,920,520 |
| 3 | Revenues | 57,714,486 |
| 4 | StockholdersEquity | 259,560,000 |
| 5 | NetIncome | -168,647,414 |
| 6 | ComprehensiveNetIncome | -168,729,721 |
| 7 | BaseVar | 322,301,120 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 2.24 |
| 9 | EconomicCapitalRatio | 3.18 |
Edgar->Model Mapping
Feature Distribution
Change over Time
